Researchers at UT Southwestern Medical Heart led a research revealed in JAMA Community Open which discovered that particular chemotherapies are related to an elevated long-term...
The FDA has accepted Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the primary and solely subcutaneous, chemo-free therapy for sufferers with EGFR-mutated non-small cell lung most...
Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
Dr. Charles M. Rudin highlighted new small cell lung most cancers therapies, together with T cell engagers, antibody-drug conjugates, in addition to...
The part 2 SANRECO examine has lately accomplished enrollment and can consider divesiran, a possible remedy for sufferers with polycythemia vera (PV),...
Sacituzumab tirumotecan (sac-TMT), together with Keytruda (pembrolizumab), as a first-line remedy for PD-L1-positive superior non-small cell lung most cancers, has demonstrated a statistically important and...
